Effectiveness of disease-modifying agents in multiple sclerosis: a longitudinal population-based comparison

被引：0
|
作者：
Veugelers, P
Bhan, V
Fisk, JD
Brown, MG
Murray, TJ
Stadnyk, K
Sketris, IS
MacKinnon-Cameron, D
机构：
[1] Univ Alberta, Edmonton, AB, Canada
[2] Dalhousie Univ, Halifax, NS, Canada
来源：
MULTIPLE SCLEROSIS | 2005年 / 11卷
关键词：
D O I：
暂无
中图分类号：
R74 [神经病学与精神病学];
学科分类号：
摘要：
引用
收藏
页码：S7 / S8
页数：2
相关论文
共 50 条
  • [1] COST-EFFECTIVENESS OF DISEASE-MODIFYING THERAPY FOR MULTIPLE SCLEROSIS: A POPULATION-BASED EVALUATION
    Noyes, K.
    Bajorska, A.
    Chappel, A. R.
    Schwid, S.
    Mehta, L. R.
    Holloway, R.
    Dick, A.
    VALUE IN HEALTH, 2009, 12 (03) : A13 - A14
  • [2] Cost-effectiveness of disease-modifying therapy for multiple sclerosis A population-based study
    Noyes, K.
    Bajorska, A.
    Chappel, A.
    Schwid, S. R.
    Mehta, L. R.
    Weinstock-Guttman, B.
    Holloway, R. G.
    Dick, A. W.
    NEUROLOGY, 2011, 77 (04) : 355 - 363
  • [3] Cost-effectiveness of disease-modifying therapy for multiple sclerosis: a population-based evaluation
    Noyes, Katia
    Bajorska, Alina
    Chappel, Andre R.
    Schwid, Steven R.
    Mehta, Lahar R.
    Holloway, Robert G.
    Dick, Andrew W.
    MULTIPLE SCLEROSIS, 2009, 15 (11): : 1398 - 1399
  • [4] Disease-modifying agents in multiple sclerosis
    Coyle, P. K.
    ANNALS OF INDIAN ACADEMY OF NEUROLOGY, 2009, 12 (04) : 273 - 282
  • [5] Disease-modifying agents in the Sonya Slifka Longitudinal Multiple Sclerosis Study
    Minden, S.
    Hoaglin, D.
    Jureidini, S.
    Hadden, L.
    Frankel, D.
    Komatsuzaki, Y.
    Outley, J.
    MULTIPLE SCLEROSIS JOURNAL, 2008, 14 (05) : 640 - 655
  • [6] Multiple Sclerosis: Overview of Disease-Modifying Agents
    Finkelsztejn, Alessandro
    PERSPECTIVES IN MEDICINAL CHEMISTRY, 2014, 6 : 65 - 72
  • [7] Depression and disease-modifying agents in multiple sclerosis: a propensity matched comparison
    Ontaneda, D.
    Cohen, J. A.
    MULTIPLE SCLEROSIS JOURNAL, 2011, 17 : S314 - S314
  • [8] The Cost of Multiple Sclerosis and the Cost Effectiveness of Disease-Modifying Agents in its Treatment
    Ceri J. Phillips
    CNS Drugs, 2004, 18 : 561 - 574
  • [9] The cost of multiple sclerosis and the cost effectiveness of disease-modifying agents in its treatment
    Phillips, CJ
    CNS DRUGS, 2004, 18 (09) : 561 - 574
  • [10] Disease progression among multiple sclerosis patients before and during a disease-modifying drug program: a longitudinal population-based evaluation
    Veugelers, P. J.
    Fisk, J. D.
    Brown, M. G.
    Stadnyk, K.
    Sketris, I. S.
    Murray, T. J.
    Bhan, V.
    MULTIPLE SCLEROSIS JOURNAL, 2009, 15 (11) : 1286 - 1294
12345